Shyam S. Chaurasia, MSc, PhD
Associate Professor of Ophthalmology & Visual Sciences; Associate Professor of Cell Biology, Neurobiology and Anatomy
Locations
- EI 827
Contact Information
Education
Master of Science (MSc), Biochemistry
Bachelor of Science (BSc), Biochemistry
Biography
Dr. Shyam S. Chaurasia was born in Gwalior, also described as the “The Medieval Majestic Indian City with Music in its Soul.” He received his bachelor’s and master’s degrees in Science with Biochemistry as his major from the esteemed Nagpur University. He obtained a PhD degree from a globally ranked School of Life Sciences, Devi Ahilya University, Indore, India. He was awarded the prestigious Department of Biotechnology sponsored Postdoctoral Fellowship, and completed his Postdoctoral training in ophthalmology/neurosciences from Emory University, Atlanta, GA.
Dr. Chaurasia took his first faculty appointment in 2006 as a scientist at the Cole Eye Institute, Cleveland Clinic, Cleveland, OH. In 2009, he decided to move to Singapore and joined the Singapore Eye Research Institute, Singapore, and Institute of Molecular and Cellular Biology, A*STAR agency as an extramurally funded principal scientist/investigator. Later, he decided to return to the United States and took his first academic appointment as Assistant Professor on a tenure-track and successfully launched NIH/NEI-funded “Ocular Immunology & Angiogenesis Lab,” studying basic and translational research in vision sciences at the University of Missouri, Columbia, MO. In 2021, he joined as an associate professor in the Department of Ophthalmology and Visual Sciences/Eye Institute at MCW.
Honors and Awards
2019, Electron Microscopy Excellence Award, University of Missouri, Columbia, MO
2018, Appeared on the local NBC News Channel in the Prime Time News, KOMU News Channel (NBC channel affiliate), Columbia, MO
2017, Electron Microscopy Excellence Award, University of Missouri, Columbia, MO
2011, Outstanding Young Research Award, Singapore Eye Research Institute, Singapore
2007, Association for Research in Vision and Ophthalmology (ARVO) Travel Award, ARVO, Rockville, MD
2006, Pineal Cell Biology Travel Award, Gordon Research Conferences, Buellton, CA
2005, X European Pineal and Biological Rhythm Society Congress Travel Award, European Pineal and Biological Rhythm Society Congress Travel Award, Frankfurt, Germany
2004, Pineal Cell Biology Travel Award, Gordon Research Conferences, Oxford, UK
2003, Mentor, BRAIN Summer Research Program, Center for Behavioral Neuroscience, Emory University, Atlanta, GA
Research Interests
Dr. Chaurasia’s Ocular Immunology and Angiogenesis Lab is funded by NIH/NEI and focuses on the Molecular Basis of Eye Diseases for the development of a highly innovative basic and translational multidisciplinary research program in the identification and validation of novel biomarkers and targets, and evaluate potential VEGF-independent Next-Generation Precision therapeutics/Medicine to treat Ocular Fibrotic and Angiogenic Diseases (OFADs). Dr. Chaurasia has substantial experience in basic and translational vision sciences, as evident from published more than 100 peer-reviewed research papers and 150+ scientific abstracts and presentations at the national and international level.
Research Experience
- Diabetic Retinopathy & Diabetic Macular Edema
- Age-related Macular Degeneration
- Retinopathy of Prematurity
- Fibrotic Eye Diseases
- Nanomedicine & Wound healing therapeutics in the Eye
- Next-Gen Tools in Precision Medicine for Retinal Degenerative Diseases
- Countermeasures Against Chemical Threats (CounterACT)
Publications
-
Recent Advances Associated with Cardiometabolic Remodeling in Diabetes-induced Heart Failure.
(Sharma G, Chaurasia SS, Carlson MA, Mishra PK.) Am J Physiol Heart Circ Physiol. 2024 Oct 25 PMID: 39453429 10/25/2024
-
Fabry Disease Rat Model Develops Age- and Sex-Dependent Anterior Segment Ocular Abnormalities.
(Erdman ME, Ch S, Mohiuddin A, Al-Kirwi K, Rasper MR, Sokupa S, Low SWY, Skumatz CMB, De Stefano V, Kassem IS, Chaurasia SS.) Invest Ophthalmol Vis Sci. 2024 Aug 01;65(10):14 PMID: 39110587 PMCID: PMC11314710 SCOPUS ID: 2-s2.0-85200939798 08/07/2024
-
(Mohan RR, Gupta S, Kumar R, Sinha NR, Landreneau J, Sinha PR, Tandon A, Chaurasia SS, Hesemann NP.) Ocul Surf. 2024 Apr;32:13-25 PMID: 38191093 SCOPUS ID: 2-s2.0-85182147133 01/09/2024
-
(Lim RR, Mahaling B, Tan A, Mehta M, Kaur C, Hunziker W, Kim JE, Barathi VA, Ghosh A, Chaurasia SS.) FASEB J. 2024 Mar 15;38(5):e23512 PMID: 38430220 PMCID: PMC11019659 SCOPUS ID: 2-s2.0-85186559682 03/02/2024
-
(Shanbagh S, Gadde SG, Shetty R, Heymans S, Abilash VG, Chaurasia SS, Ghosh A.) Exp Eye Res. 2024 Jan;238:109713 PMID: 37952722 SCOPUS ID: 2-s2.0-85178139041 11/13/2023
-
(Babu VS, Mallipatna A, Dudeja G, Shetty R, Nair AP, Tun SBB, Ho CEH, Chaurasia SS, Bhattacharya SS, Verma NK, Lakshminarayanan R, Guha N, Heymans S, Barathi VA, Ghosh A.) Transl Res. 2023 Nov;261:41-56 PMID: 37419277 SCOPUS ID: 2-s2.0-85167435325 07/08/2023
-
(Low SWY, Lim RR, Grant DG, Patterson S, Chaurasia SS.) Res Sq. 2023 Aug 07 PMID: 37609321 PMCID: PMC10441459 08/23/2023
-
Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.
(Mahaling B, Low SWY, Ch S, Addi UR, Ahmad B, Connor TB, Mohan RR, Biswas S, Chaurasia SS.) Pharmaceutics. 2023 Jul 22;15(7) PMID: 37514191 PMCID: PMC10383092 SCOPUS ID: 2-s2.0-85166338712 07/29/2023
-
Mustard Gas Exposure Actuates SMAD2/3 Signaling to Promote Myofibroblast Generation in the Cornea.
(Sinha NR, Tripathi R, Balne PK, Suleiman L, Simkins K, Chaurasia SS, Mohan RR.) Cells. 2023 Jun 02;12(11) PMID: 37296653 PMCID: PMC10252656 SCOPUS ID: 2-s2.0-85163141524 06/10/2023
-
(Shanbagh S, Matalia J, Kannan R, Shetty R, Panmand P, Muthu SO, Chaurasia SS, Deshpande V, Bhattacharya SS, Gopalakrishnan AV, Ghosh A.) Indian J Ophthalmol. 2023 May;71(5):2143-2151 PMID: 37203095 PMCID: PMC10391435 SCOPUS ID: 2-s2.0-85159765396 05/19/2023
-
Mustard gas exposure instigates retinal Müller cell gliosis.
(Mahaling B, Sinha NR, Sokupa S, Addi UR, Mohan RR, Chaurasia SS.) Exp Eye Res. 2023 May;230:109461 PMID: 37023936 PMCID: PMC10157651 SCOPUS ID: 2-s2.0-85151717505 04/07/2023
-
(Suresh Babu V, Kizhakeyil A, Dudeja G, Chaurasia SS, Barathi VA, Heymans S, Verma NK, Lakshminarayanan R, Ghosh A.) Pharmaceutics. 2022 Nov 18;14(11) PMID: 36432697 PMCID: PMC9694048 11/27/2022